The 9 analysts offering 12-month price forecasts for Stoke Therapeutics Inc have a median target of 65.00, with a high estimate of 83.00 and a low estimate of 34.00. The median estimate represents a +159.79% increase from the last price of 25.02.
The current consensus among 10 polled investment analysts is to Buy stock in Stoke Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.61
Reporting Date Mar 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.